© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to February
first patented BACE1 protease inhib. of series
Ph. II/III in Alzheimer’s, discontinued (tox.)
from phenotypic screen and SBDD
J. Med. Chem., Feb. 15, 2021
Shionogi Pharmaceutical, Osaka, JP
9. The Shionogi BACE1 aspartyl protease inhibitor, atabecestat (JNJ-54861911) is an oral, brain-penetrant compound that was advanced into the EARLY Ph. IIb/III clinical trial for treatment of preclinical Alzheimer’s…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.